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A major objective of this article is to examine the research implications of recently available genome-
wide expression proﬁles of cartilage from human osteoarthritis (OA) joints. We propose that, when
viewed in the light of extensive earlier work, this novel data provides a unique opportunity to reorient
the design of experimental systems toward clinical relevance. Speciﬁcally, in the area of cartilage explant
biology, this will require a fresh evaluation of existing paradigms, so as to optimize the choices of tissue
source, cytokine/growth factor/nutrient addition, and biomechanical environment for discovery. Within
this context, we ﬁrstly discuss the literature on the nature and role of potential catabolic mediators in OA
pathology, including data from human OA cartilage, animal models of OA, and ex vivo studies. Secondly,
due to the number and breadth of studies on IL-1b in this area, a major focus of the article is a critical
analysis of the design and interpretation of cartilage studies where IL-1b has been used as a model
cytokine. Thirdly, the article provides a data-driven perspective (including genome-wide analysis of
clinical samples, studies on mutant mice, and clinical trials), which concludes that IL-1b should be
replaced by soluble mediators such as IL-17 or TGF-b1, which are much more likely to mimic the disease
in OA model systems. We also discuss the evidence that changes in early OA can be attributed to the
activity of such soluble mediators, whereas late-stage disease results more from a chronic biomechanical
effect on the matrix and cells of the remaining cartilage and on other local mediator-secreting cells.
Lastly, an updated protocol for in vitro studies with cartilage explants and chondrocytes (including the
use of speciﬁc gene expression arrays) is provided to motivate more disease-relevant studies on the
interplay of cytokines, growth factors, and biomechanics on cellular behavior.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Current research into osteoarthritis (OA) is driven by at least
three over-arching paradigms. Firstly, there is consensus that OA is
a disease of the whole joint organ, which predicts a pathogenic role
for all intra-synovial tissues including articular cartilage, synovial
membrane, meniscal ﬁbrocartilage, intra-articular ligaments, peri-
articular tissues, and sub-chondral bone. Thus, the biological and
biomechanical interplay between these tissues that ultimately.D. Sandy, 1750 West Harrison
, USA. Tel: 1-312-942-8249;
andy), deva_chan@rush.edu
arkus_a_wimmer@rush.edu
ternational. Published by Elsevier Lleads to joint dysfunction remains a topic of high interest. Next, and
closely related to the “whole joint” concept, is the notion that OA is
not a single disease but a spectrum of pathologies that differ in the
nature of the initiating event(s) and the subsequent natural history.
Accordingly, OA subtypes can be characterized by the relative
impact of factors such as genetic predisposition1, joint trauma2,
aberrant biomechanics3, and aging4. A third paradigm states that
essentially all OA subtypes exhibit some degree of inﬂammation
and that many of the pathogenic cellular changes are part of an
innate pro-inﬂammatory response to stressors such as altered
biomechanics, pH, radicals, and matrikines or DAMPs5,6. Recog-
nizing the importance of these paradigms, we discuss here how the
ready availability of methods and instrumentation for analysis of
the genome, epigenome, transcriptome, and proteome of OA has
markedly increased the opportunities for seminal discovery of new
pathogenic pathways.td. All rights reserved.
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basic and translational research in OA continues to focus on artic-
ular cartilage and chondrocytes, as cell-mediated loss of this tissue
from the bone end, is an event common to all sub-types of the
disease, and the degree of cartilage damage is often viewed as the
read-out that can best measure the effectiveness of interventions.
Further, biomechanically induced disturbance in the homeostatic
control of articular cartilage tissue contributes substantially to OA
pathology, and therefore the delineation of mechanistic links be-
tween mechanical forces and chondrocyte responses continues to
occupy a central position in the area. In this review, we discuss how
new “omics” data can be used to redesign experiments examining
the interplay between biomechanical stimuli (compressive, shear,
and tensile forces) and pro-inﬂammatory pathway responses that
promote cartilage degeneration. As an example, we provide a
critical evaluation of the published data that have focused on IL-1b
as the key pro-inﬂammatory cytokine both in vitro and in vivo, and
in both cell biological and biomechanical studies of OA.History of IL-1b use in OA research
The use of IL-1b as a tool to study tissuematrix remodeling in OA
was an almost inevitable outcome of the manner of its initial
description. In 1977, the laboratory of Dame Honor Fell7 described a
protein that was synthesized by explanted porcine synovial tissue
and induced the destruction of live cartilage such that (quote) “the
cartilage became reduced to a mass of ﬁbroblast-like chondrocytes
without matrix.” This factor was given the name “catabolin8” and
subsequently shown by protein chemistry to be IL-1b9. Based
largely on the impact of this seminal work, the effects of IL-1b have
been studied in great detail by researchers interested in describing
the cell responses in cartilage matrix turnover and synovial
inﬂammation during OA pathogenesis. Indeed, data from in-
vestigations with IL-1b are a major component of the knowledge
base that supports many of the present-day basic and pre-clinical
studies on OA. Further, the consensus that OA is a chronic non-
healing wound of the “joint organ,” which has an innate inﬂam-
matory and ﬁbrotic component10e12, has further motivated studies
on the role of cytokines in OA pathogenesis6,11. As a result, in-
vestigators using IL-1b or examining its endogenous gene expres-
sion in OA research often introduce the studies with the premise
that IL-1b is the “major cytokine” promoting joint tissue pathology
in OA. However, the data in recent publications from disparate
areas has persuasively argued against the notion of a central role for
this cytokine.IL-1b is present in essentially normal concentrations in joint
ﬂuids from early and late OA
A major role for IL-1b in mediating OA pathogenesis should be
supported by an elevated level of the cytokine in the synovial
ﬂuid of OA patients. However, this is not the case, as multiple
studies13e15 have reported that the level in joint ﬂuid aspirates
collected early after injury or in advanced OA is essentially
identical to that measured in normal ﬂuids (~10 pg/mL). More-
over, the concentration of IL-1 receptor antagonist (IL-1Ra,
~10 ng/mL), which competes with IL-1b by binding to its recep-
tor, is present in concentrations that far exceed the concentration
of IL-1b itself. In one study of 42 OA patients16, the average IL-
1Ra/IL-1b (w/w) ratio in the synovial ﬂuid was about 1800:1,
making it highly unlikely that the IL-1b in the ﬂuid ever binds to
IL-1R1 on cells within the joint. It is notable that, in similar
samples, IL-6 and IL-8 are found in 20-fold increased amounts
(up to 20 ng/mL for IL-6)17,18.Clinical trials targeted at blocking IL-1b signaling in OA
patients have shown no marked efﬁcacy
Treatment of OA patients with protein biologics to block IL-1
stimulation has given inconclusive results19. Monoclonal anti-
bodies to IL-1R administered subcutaneously20 were well tolerated
in symptomatic patients; however, no robust clinical beneﬁt was
observed. In contrast, 150 mg of IL-1Ra given by intra-articular
injection21 showed an approximate 20% improvement in pain and
global OA scores for 3 months. In a different study design22, the
same intra-articular dose of IL-1Ra was given at 2 weeks after ACL
injury, and, in this case, a minor “clinically meaningful” beneﬁt was
seen at 2 weeks after the injection. However, there was no signif-
icant change in the level of synovial ﬂuid IL-1b, and longer-term
effects have not been reported.
Studies with mutant mice do not support a direct role for IL-
1b in murine OA
The elimination of genes that control IL-1b-stimulated path-
ways (such as IL-1b itself, caspase-1, or iNOS) actually results in the
development of spontaneous OA23. In addition, blockade of NLRP3
(an inﬂammasome component) or IL-1RI24 does not protect against
loss of matrix components in murine cartilage explants, and abla-
tion of MyD8825 does not prevent development of experimental
OA. Notably, several studies in a murine model of post-traumatic
OA, induced by intra-articular fracture, have implicated IL-1b as a
major inﬂammatory mediator of cartilage degeneration26,27. How-
ever, to what extent the reported increases in serum and synovial
ﬂuid levels of IL-1b in the acute phase26 of the model is due to an
incipient OA or a response to bone fracture is unknown. Further-
more, it is difﬁcult to interpret the reported protection against OA
in this model, using the MRL/MpJ strain27, which responds with a
decrease in IL-1b response, since this mouse has a complex
multigenic immune-modulated phenotype28e30, and protection
may be the result of modulation in other cytokine and growth
factor responses.
Supra-physiologic concentrations of IL-1b are required to
induce OA-like changes in cartilage explants and chondrocyte
cultures
Although many in vitro studies (for example31e34) have
demonstrated that the presence of IL-1b can induce degradation of
the proteoglycan and collagen components of extracellular matrix
(ECM), they were all performed using supra-physiological levels of
IL-1b, ranging anywhere from 1 ng/mL to as much as 1000 ng/mL,
compared to <10 pg/mL in body ﬂuids. There is also ongoing
research on the effect of IL-1b on micro-RNAs (miRs), including
miR-145 and Smad pathway signaling35, miR-140 and OA-like
matrix changes36,37, as well as miR-146 and inﬂammation38; how-
ever, these studies also employ IL-1b at 5e10 ng/mL.
The presence of IL-1b -inducible factors in OA model systems
does not implicate IL-1b itself
This widely-studied and complex topic is covered in a recent
detailed review39 on receptors and signaling pathways of IL-1
family members. Brieﬂy, the major downstream effects in IL-1b
stimulated cells are mediated by activation of AP-1 and NF-kB
families of DNA-binding proteins and their interaction with TRE
and kB sites in the promoter regions of target genes. In the regu-
lation of transcription factor binding to kB sites, IL-1b is part of a
group of over 150 different ligands that can signal through this
pathway40. These include, for example, TLR ligands, LPS, AGE,
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factors such as M-CSF, NGF and PDGF, stress molecules such as
HSP60, hyaluronan oligosaccharides, anti-FAS, and Apo1. Binding at
kB sites controls transcription of an equally large number of diverse
target genes including growth factors (GM-CSF, IGFBP-2, M-CSF,
PDGFB, VEGFc), metalloproteinase (ADAMTS541, MMP1, -9, and -13)
and additional inﬂammatory mediators (IFN-g, ICAM-1, tenascin C,
Vcam1, uPA, COX2, iNOS, IL-1a/b, IL-1ra, IL-2, -6, -8, -11, -12, -15,
TNFa/b). Relevant to this article, both IL-1R1 and IL-1R3 have a
cytoplasmic subdomain (Toll/IL-1R) that has high structural and
functional homology with the cytoplasmic domain of Toll-like re-
ceptors (TLRs), explaining why the cellular response to TLR ligands
and IL-1 family ligands are often the same (for detailed
reviews42,43).
Genome-wide expression data suggests that activation of
matrix genes, but not IL-1b-responsive genes, is centrally
important to cartilage pathology in human OA
The idea that IL-1b is not involved in OA has most recently been
supported by ‘large data’ gene expression array studies. There are
now at least eight papers44e51 that have presented high-density
coverage or genome-wide analysis of differentially expressed
genes in cartilage from advanced human OA. For example, in one
transcriptomic study48, data was obtained for hip and knee carti-
lages taken at arthroplasty and compared to hip cartilage taken
during surgery for femoral neck fracture. The data were examined
for differential expression at the single gene level and then further
analyzed for pathway associations. Firstly, in comparisonwith non-
affected cartilage, only a relatively small number of genes were
changed in the same direction (increased or decreased expression)
for both hip and knee OA cartilage and therefore can be tentatively
considered as disease-related, independent of the joint of origin.
Increased mRNA transcript abundance in both types of OA carti-
lages were seen for collagens (COL2A1, COL5A1, COL5A2, COL8A2,
COL11A1, COL13A1), PCOLCE (involved in collagen biosynthesis),
glycosyltransferases involved in glycosaminoglycan synthesis
(EXTL2, GALNT1, CHST6), cell-matrix ligands/receptors (NCAM1,
ITGA11, SPARC), serine proteinases (HTRA1, SERBP1), and cell pro-
liferation mediators (PDGFC, PDGFRL). Increased expression of
cytokine genes was seen for IL-8, IL-12 and IL-17. Genes down-
regulated in OA cartilage were stress response mediators (SOD2,
MT1M, ELL2, HIG2, GADD45A, GYG1) and intracellular signaling
molecules (HMGB2, AKT3, JAK2, EFNA1). In a separate study50, gene
expression was compared in cartilage from normal autopsy, early
OA autopsy, and advanced OA arthroplasty. This study similarly
revealed activation of ten collagen genes (excluding COL10A1) in
cartilage from advanced stage OA. The authors discussed the pos-
sibility that the results may have been confounded by mRNA
instability before tissue collectione a technical issue that remains a
matter for further analysis. In fact, since all of the expression
studies44e49,51 have been done on cartilage from joints with
advanced OA, it is unknown whether similar or markedly different
changes will be seen when cartilage from “early” OA (such as after
ACL rupture) can be obtained for analysis.
Notably, the enhanced expression of multiple collagen genes in
both early and late human OA cartilages is not seen in laser-
dissected cartilage from murine surgically-induced OA52, whether
analyzed at early time points (1 and 2 weeks) or at the time of
surface ﬁbrillation (6 weeks). However, in the same model,
enhanced expression of multiple collagen genes (Col3a1, Col4a2,
Col5a1, Col12a1, Col14a1, Col16a1, Col22a1) and collagen processing
enzymes (Pcolce and Lox1) was seen at 2 and 4 weeks in tissues
pooled from the whole joint organ53. With regard to the topic of
this review, most of the disease-related genes identiﬁed in humanandmurine OA are not typically altered by IL-1b, or they are altered
in the opposite direction to the changes seen in diseased human
cartilages. For example, while collagen and glycosaminoglycan
synthesis genes are upregulated in OA, chondrogenesis is markedly
inhibited by IL-1b in human MSCs54. This dichotomy has also been
conﬁrmed by proteomic analyses, where samples were from hu-
man normal and OA cartilage explants either untreated55 or treated
with IL-1b (10 ng/mL)56. The major functional group identiﬁed as
OA-related in untreated explants was ECM turnover proteins such
as collagens; however, with IL-1b treatment, the major proteins
identiﬁed as “OA-related” did not include the collagens.
Pathway analysis implicates IL-17, HMGB1 and COL5A1, but
not IL-1b, in OA pathology
Another approach to identifying OA-related cellular responses is
to describe the normal vs OA differential in terms of gene pathways.
For example, using Ingenuity Canonical Pathway Analysis48, 60
pathways emerged from such a search, but none were directly
related to either “incoming” or “outgoing” IL-1 b signaling events.
However, over half of these pathways appeared to be related to OA
development, and, remarkably, ten were directly linked to IL-17
signaling. Other notable genes (with the number of pathways
indicated here in brackets) were related to IL-15 [3], ILK [2], Wnt/b-
catenin [2], and pluripotency [2], with a single pathway associated
with the following: JAK, HMGB1, IL-6, IL-8, IL-12, OSM, p53, nitric
oxide, O-glycan biosynthesis, AKT, p38/MAPK, NF-kB, caveolae,
CCR5, hypoxia and insulin receptor.
Indeed, if the individual genes suggested from the differential
between normal hip and both hip and knee OA are compared to the
pathway analysis of normal hip vs OA hip, the combined data
identiﬁes IL-17, IL-15, IL-12, IL-8, HMGB1/2, COL5A1, HIG2, and
GYG1 as some of the genes most highly “relevant” to OA pathology.
Furthermore, if the analysis is conﬁned to genes that have previ-
ously been implicated in OA, the authors48 identiﬁed up-regulation
of ADAMTS1, ADAMTS5, ADAMTS9, MMP1, MMP3, MMP23, SOD2,
COL2A1, COL5A2, COL9A1, and COL11A1 and down-regulation of
CCL20, ATF3, and GADD45a/b as OA-relevant. It should also be
noted that some members of this particular list of “most-relevant”
genes have been chosen primarily on the basis of the human OA
transcriptome in end-stage hip disease48. Nonetheless, a central
role for IL-17 in experimental arthritis has been a common theme in
many studies57 and is further supported by the fact that it inhibits
(albeit at supra-physiologic concentrations) chondrogenic differ-
entiation of humanMSCs58, synergizes with TL1A in the expression
of Adamts5 by macrophage-like cells59, and induces murine joint
destruction after intra-articular injection60.
Gene pathway analyses clearly implicate biomechanical
effects in the development of OA
Biomechanical treatments, such as a single injurious compres-
sion of bovine cartilage explants (maximum peak contact stress of
~20e30 MPa), resulted in decreased expression of adhesion mole-
cules, matrix proteases, and growth factors but an increase in
metabolic-pathway enzymes, chemokine and cytokine receptors,
signal transduction markers, and transport proteins61,62. Gene
pathway analysis of human OA cartilages has uncovered many ex-
amples of genes involved in the same pathways49. Another example
is the modulation of the HMGB1 pathway seen in OA cartilage48,
which is also seen after mechanical injury to the superﬁcial zone
cartilage (through blunt impact or scratching in vitro63) that gen-
erates soluble HMGB1 resulting in activated migration of the resi-
dent progenitor population and induced expression of
chondrogenic markers. Likewise, the many links to MAPKs in the
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connected to the ﬁnding that MAPKs become transiently phos-
phorylated during a number of cyclic and static compression pro-
tocols imposed on cartilage explants64,65. Of particular interest in
the current context is the fact that late-stage human OA is invari-
ably accompanied by an over-expression of multiple collagen genes
in the cartilage, which is suggestive of a prolonged joint-wide
activation of pro-ﬁbrogenic growth factor signaling, including
CTGF66,67 and TGF-b168. Notably, treatment of normal cartilage
with physiologic levels of unconﬁned dynamic compression for
30 min69 also induced similar pro-ﬁbrotic/anti-chondrogenic re-
sponses. Indeed, whether these pro-ﬁbrotic factors are augmented
by other mediators produced by mechanically challenged tissues in
the OA joint, such as IL-1748, should represent an area for further
research.
Practical uses of genome-wide expression data: application to
in vitro cartilage and chondrocyte culture models for the
discovery of new pathways that link biomechanical and
biological stimuli during OA pathogenesis
Cartilage explant and 3D chondrocyte culture systems remain in
wide use as experimental models for examining the interplay be-
tween biomechanical forces imposed on the specimen in vitro and
corresponding cellular responses leading to OA pathogenesis path-
ways. We discuss here some practical uses of human OA-related
expression data44e51 and indicate how they might motivate what
appear to be more clinically relevant studies in this area. The basic
framework is presented in three sections that address the most
critical issues in terms of study design and should apply equally to
experiments with biomechanical and/or biological perturbation.
(1) As a tissue source, full-depth (~1e2 mm) human articular
cartilage disks (3 mm punch) from the tibial plateau or
femoral condyle of normal knees (50e80 years) and the
equivalent from full-depth, surface-intact articular cartilage
from OA knees (50e80 years) should be used if possible.
Human articular cartilage is preferred for consistency with
the published OA-related expression analyses, but full-depth
mature (>18 months) bovine or porcine articular cartilages
can also be used, as they are readily available to most
investigators.
(2) We suggest IL-17 should be included in any OA-inductive
culture medium. The use of this cytokine (or pathway-
linked cytokines such as IL-2270) is proposed on the bases
of (1) the OA tissue gene expression and pathway analysis
reviewed above, (2) its pro-arthritic activity in murine OA
models57,60, (3) its capacity to inhibit chondrogenesis of
human MSCs through suppression of PKA activity and inhi-
bition of SOX9 phosphorylation58, and (4) its capacity to
induce ADAMTS1, -4, and -5, synergistically with tumor ne-
crosis factor-like protein 1A, in human macrophage cul-
tures59. Furthermore, IL-17 signals via DNA binding of CEBPA
components, which is important in vivo since CEBPA-positive
M2 macrophages are abundant in chronic inﬂammation and
ﬁbrosis of the synovium71. In addition, increased expression
of IL-17 is seen in synovial tissues in inﬂammatory phases of
OA72, and its binding to epithelial cells induces expression of
COL5A173 via a TGF-b1/ALK5 signaling mechanism. Its rela-
tionship to TGF-b1-driven overexpression of collagen in
scleroderma and ﬁbrosis74e77 is also relevant, since OA pro-
gression has been linked to both joint tissue ﬁbrosis12,78,79
and subchondral bone marrow ﬁbrosis80. A pro-ﬁbrotic ef-
fect of IL-17 is further underlined by the ﬁnding that
mesenchymal-speciﬁc deletion of Cebpa attenuates murinepulmonary ﬁbrosis77. As a separate issue, since the majority
of OA cartilage expression proﬁling showed activation of
matrix components (such as ACAN, COL2A1, COL3A1,
COL4A1, COL12A1, PCOLCE), it seems reasonable that one or
more growth factors found in elevated levels in OA synovial
ﬂuids (TGF-b1, CTGF, PDGF, EGF, FGF-2, VEGF, GDF5) should
also be included in the OA-inductive medium. For example,
TGF-b1 and CTGF could be added because they both have
well-established pro-ﬁbrotic effects highly relevant to OA
pathogenesis. These include the action of TGF-b1 in induc-
tion and progression in murine OA models11,68, the correla-
tion of elevated CTGF concentration in synovial ﬂuids with
radiographic severity in human OA67, and the induction of
synovial ﬁbrosis in murine OA, with concurrent enhanced
expression of MMP-13, ADAMTS-4, and ADAMTS-581.
Regarding the choice of IL-17, TGF-b1, and CTGF, it should be
noted that similar recommendations could be made for the
addition of any one or more of the factors identiﬁed by
genome-wide screening as “OA-related” (e.g., IL-15, IL-12, IL-
8, PDGF, EGF, FGF-2, VEGF, GDF5).
(3) The primary readout should be gene expression analysis,
which can be done on a small group of genes with known OA
relevance or on pathway-based arrays with predicted rele-
vance. The sensitivity, speciﬁcity, accuracy, and reproduc-
ibility of these methods can generate important data from
cartilage samples in the low milligram range. This is impor-
tant because it makes it feasible to analyze for expression
changes in different depth zones of articular cartilage after
treatment in vitro. Indeed, paramount in all these studies is
the recognition that there is a well-established82,83 depth-
dependent difference in the response of cartilage cells to
OA-inductive conditions in vivo. For example, expression
comparisons of different depths of normal and surface-intact
OA human articular cartilages82 (obtained by micro-
dissection into superﬁcial, middle and deep zones) showed
that the up-regulation (about 20-fold) of ACAN and COL2A1
in the deep zone of the OA samples was not seen in the su-
perﬁcial zone. This supports earlier studies84 in which
chondrocytes isolated frommicro-dissected zones of mature
bovine cartilage were shown to exhibit distinct metabolic
proﬁles and responses to inﬂammatory mediators.Summary
The availability of genome-wide expression proﬁles of cartilage
from human OA joints can be used to reorient the design of clini-
cally relevant, in vitro experimental systems in the laboratory. A
fresh evaluation of existing paradigms can now be undertaken so as
to optimize the choice of tissue source, cytokine, growth factor or
nutrient addition, biomechanical environment, and readout anal-
ysis for discovery. Since biomechanical modulation of genomewide
alterations is relatively new to this area, it will be essential that
experimental parameters (e.g., tissue strain, boundary conditions,
geometry) are reported and considered in the interpretation and
reproduction of the generated data. Going forward, the use of
commercially available pathway-linked gene expression arrays
should help unravel the implications of the laboratory data for
treatment of the human disease.
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